| Literature DB >> 31085085 |
Xiuxing Liu1, Yichen Xiao1, Yuan Pan1, He Li1, Song Guo Zheng2, Wenru Su3.
Abstract
Autoimmune diseases (ADs), which are common immune-mediated inflammatory syndromes, are characterized by an imbalance between T effector (Th)1/Th17 cells and T regulatory cells. Interleukin (IL)-33, a member of the IL-1 family, induces inflammatory disease development by mediating type 2 immune responses. Recently, IL-33/ST2 axis was reported to induce autoimmunity involving Th1 and Th17 cells. In this review, we focus on the expression, regulation and function of IL-33/ST2 pathway in the context of autoimmune disorders. We discuss the clinical potential of this signaling pathway in predicting disease activity and severity and offer possible future therapeutic alternatives.Entities:
Keywords: Autoimmune diseases; Interleukin-33; ST2; Th1; Th17; Type 2 immune responses
Year: 2019 PMID： 31085085 DOI： 10.1016/j.cytogfr.2019.04.004
Source DB: PubMed Journal: Cytokine Growth Factor Rev ISSN： 1359-6101 Impact factor: 7.638